Therapeutic Tactics in patients with Polypous Rhinosinuitis, depending on the Morphological Picture of the Nasal Cavity

Kurbanov Elmurod Xushvaktovich; Eshkobilova Surayo Turaevna

doi:10.17605/cajmns.v2i2.125

Kurbanov Elmurod Xushvaktovich Samarkand State Medical Institute Department of Otorhinolaryngology and Histology Samarkand, Uzbekistan
Eshkobilova Surayo Turaevna Samarkand State Medical Institute Department of Otorhinolaryngology and Histology Samarkand, Uzbekistan

DOI: https://doi.org/10.17605/cajmns.v2i2.125

Keywords: polyposis rhinosinusitis, rhinosurgery, multifactorial, conservative glucocorticosteroid

Abstract

Chronic polyposis rhinosinusitis (CPMS) is a multifactorial polyetiological disease [1].The problem of nasal polyps and paranasal sinuses remains relevant, since the main aspects of this pathology (etiological, pathogenetic, immunological, therapeutic) have not been fully resolved all over the world. The disease is accompanied by a decrease in the patient's quality of life. According to the latest position papers on rhinosinusitis and nasal polyps of the European Academy of Allergology and Clinical Immunologe (EAACI Position Paper on Rhinosinusitis and Nasal Polyps - EPOS, 2007; 2012), the prevalence of CPMS in the population ranges from 1 to 4% , while men get sick more often [2]. The disease often occurs in people of working age at the age of 25-35. Nasal polyps are a manifestation of the so-called special form of chronic rhinosinusitis, caused by a bacterial or fungal infection, with the formation of chronic eosinophilic inflammation.

References

Bezrukova E.V., Khmelnitskaya N.M. Revealing the relationship between
morphological changes in polyposis tissue and the concentration of some cytokines in the nasal secretion. Russian otorhinolaryngology. 2013; 5 (66): 14-18.
Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper
on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012; 50 (1): 1-12.
doi: 10.4193 / Rhino12.000
Hopkins C, Slack R, Lund V, et al. Long¬term
outcomes from the English national comparative audit of surgery for nasal
polyposis and chronic rhinosinusitis. Laryngoscope. 2009; 199 (12): 2459-2465.
doi: 10.1002 / lary.20653
Kennedy DW. Endoscopic sinus surgery. Laryngoscope. 1993; 102 (5): 578.
doi: 10.1288 / 00005537¬199305000¬00019
King JM, Caldarelli DD, Pigato JB. A review of revision functional
endoscopic sinus surgery. Laryngoscope. 1994; 104 (4): 404-408.
doi: 10.1288 / 00005537¬199404000¬00002
Vishnyakov V.V. Polypoid rhinosinusitis: conservative or surgical treatment? Effective pharmacology. 2011; (1): 46-49.
Varvyanskaya A, Lopatin A. Efficacy of long¬term low¬dose macrolide
therapy in preventing early recurrence of nasal polyps after endoscopic sinus
surgery. Int Forum Allergy Rhinol. 2014; 4 (7): 533-541.
doi: 10.1002 / alr.21318
8 . Piskunov G.Z., Bobacheva T.Yu. Chronic polyposis rhinosinusitis: promising treatment options. Academic journal of Western Siberia. 2012; (1): 15.
9. Yamada T, Fujieda S, Mori S, et al. Macrolide treatment
decreased the size of nasal polyps and IL¬8 levels in nasal lavage. Am J Rhinol. 2000; 14 (3): 143-148.
doi: 10.2500 / 105065800782102717
10. Bachert C, Gevaert P, Holtappels G, et al.
Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. The J Allergy Clin Immunol. 2001; 107 (4): 607-614.
doi: 10.1067 / mai.2001.112374
11. Zhang N, Holtappels G, Claeys C, et al. Pattern of inflammation and impact of Staphylococcus aureus enterotoxins in nasal polyps from southern China. Am J Rhinol. 2006; 20 (4): 445-450.
doi: 10.1007 / s11882¬009¬0031¬4